In 1743 the famous English anatomist William Hunter wrote 'an ulcerated cartilage is a trouble-some problem… that, once destroyed, it is not recovered' [1] . Today, more than 250 years later, cartilage damage is still an issue for physicians and patients and there is still no universally accepted and successful treatment approach for damaged AC. However, the result of research into novel surgical therapies developed over the last two decades, described in this article, have the potential to consign this statement to history.
Importance of knee cartilage defects
Articular cartilage lesions are common. In patients undergoing arthroscopic investigation for knee symptoms the incidence of cartilage defects has been found to be 61% [2] and 63% [3] and the prevalence of work-or sport-related articular lesions has been reported at 22% and 50% [4, 5] . Furthermore, in patients with anterior cruciate laxity the incidence of articular pathology is as high as 54% [6] . Although more common with age, these injuries are also frequent in patients less than 55 years old [3, 7] , in whom a prosthetic joint replacement, with a limited lifespan, is not recommended. Therefore alternative treatments are required. Focal AC defects are most often traumatic in origin, resulting from a high-load impact or repetitive shear and torsional loads on the superficial zone of articular cartilage [8] . A small proportion of lesions are caused by osteochondritis dessicans (less than 5%) [9] . Focal formed from embryonic mesenchyme in a complex and incompletely understood developmental process [10] . The two principal components of AC are proteoglycans, negatively charged glyocsaminoglyan chains that swell and hydrate AC, and collagen type II, a fibrillar collagen that traps the proteoglycans and provides tensile strength.
This ECM is specialised to cope with its singular biomechanical environment; to regain a functional joint, cartilage defects would ideally be replaced by tissue of this precise composition.
Injury to some musculoskeletal tissues, such as bone, result in recapitulation of embryonic development processes and regeneration of fully functional tissue identical to the pre-injured tissue. However, there are several barriers to intrinsic articular cartilage repair: 1) It is avascular, meaning that the nutrients required for energetic repair processes and the removal of metabolic waste products are limited by diffusion to/from surrounding tissues. 2) It is relatively acellular, therefore few cells are available to effect repair. These obstacles conspire to limit repair of defects to a fibro-cartilaginous substitute tissue with different molecular composition (more type I collagen, less proteoglycan) and biomechanical behaviour (less proteoglycan and collagen type II, more collagen type I), compared to the original hyaline tissue [11, 12] .
Despite this clear pathological response to injury the natural history of untreated AC lesions is not fully understood [13] . Shelbourne et al. (2003) reported a series of patients identified with AC defects discovered at the time of arthroscopic cruciate ligament reconstruction. Patients left with untreated AC lesions had similar subjective patient scores at an average follow up of nine years than control subjects with no AC defects. Interestingly, the authors also noted that a number of patients with significant AC defects have no/mild clinical symptoms [5] . In another treatment intervention trial patients treated only with debridement and no surgical repair procedure showed spontaneous improvement [14] . Therefore, although some lesions will be asymptomatic, AC defects have the potential to manifest as continued joint pain, impaired movement and functional disability, that will need treating in a F o r P e e r R e v i e w O n l y carefully selected group of patients. Additionally, it is known that AC defects increase the risk of osteoarthritis, which may require knee replacement [15] . Therefore, it is desirable to intervene not only to reduce current morbidity but also in order to reduce the likelihood of future joint disorder.
Patient selection and indication for surgery
A wide-range of non-specific symptoms may lead clinicians to consider that an AC defect is the source of a patient's pain, including locking, pain at rest, swelling, pain with activity, instability and retropatellar crepitus [16, 17] . Approximately two thirds of patients with chondral defects have associated ligamentous or meniscal pathology and AC damage has been reported in association with 23% of ACL injuries and 54% of knees with chronic anterior cruciate ligament laxity or instability [6] . Focal AC defects are distinct from osteoarthritis, which often involves more widespread cartilage damage and prominent subchondral bony changes, is predominantly a disease of old age, and has a chronic, gradually worsening course.
Cartilage lesions are graded I-IV according the International Cartilage Repair Society scale [18] . Grade I lesions are nearly normal with only superficial fissures, grade II lesions extend less than 50% of cartilage depth, grade III are severely abnormal lesions extending more than 50% of cartilage depth, but not into the subchondral bone, and grade IV lesions include the subchondral bone.
Clinical examination is supported by arthroscopic assessment, the gold standard investigation for chondral defects, which allows direct visualisation of the chondral surface. In addition, magnetic resonance imaging (MRI) has a high sensitivity and specificity to detect chondral defects (greater than 95% for grade III lesions [19] ).
High resolution MRI can provide sufficient information for operative planning, and might in future obviate the need for diagnostic arthroscopy. Most importantly, the commonly occurring asymptomatic AC defect makes it essential that care is taken during clinical examination and investigations to determine that findings correlate with clinical symptoms, therefore ensuring that treatment is not misdirected [5] .
Patient selection and indications for surgery vary according to the treatment type, and are considered further below.
Current treatment options
Orthopaedic surgeons have developed a wide arsenal of treatment options for treating focal knee AC defects [20] . Those most commonly employed today include, but are not limited to: 1) arthroscopic debridement, in which loose cartilage is trimmed, 2) microfracture, in which bone marrow based repair is stimulated, 3) autologous osteochondral grafting, in which bone-cartilage plugs are harvested from non-weight bearing joint sites and implanted directly into the defect, and 4) autologous chondrocyte implantation, a two-stage procedure involving harvest of chondrocytes, growth in vitro, then re-implantation.
Which treatment is chosen depends on several factors, including size of lesion, availability of particular treatments and the age and requirements of the patient.
Small lesions may be conservatively managed with arthroscopic debridement and careful monitoring [14, 21] , whereas more extensive lesions require greater intervention. The first choice treatment for lesions less than 2.5 cm 2 is bone marrow stimulation by microfracture [8, [22] [23] [24] . Larger lesions may be treated by mosaicplasty [17] , this technique is limited by the availability of donor tissue, or by autologous chondrocyte transplantation, which is becoming more widely available [8] . Other treatments, such as abrasion chondroplasty and the use of carbon fibre pads, are either less widely practised, or have been superseded, and are therefore not discussed. 1959 [25] , was prevalent until the advent of microfracture in the 1990s [26] . Pridie drilling uses a hand-driven or motorised drill to penetrate the subchondral plate. This is thought to cause heat-related tissue damage, whereas microfracture uses a gentler arthroscopic awl, which does not generate significant heat [27, 28] .
Arthroscopic debridement
Microfracture is now more popular than other bone marrow stimulation techniques (drilling and arthroscopic abrasion arthroplasty [29] ).
Microfracture has demonstrated good or excellent results in 60-80% of patients [27, 30, 31] . There is some evidence that MF works best in patients under 40 years old that might have intrinsically superior healing responses to those in older patients [32] . It benefits from the low-morbidity of an arthroscopic procedure with a relatively quick recovery period and low complication rate [30, 33] .
Treatable lesions are 1-2.5 cm 2 large, and well shouldered with protected edges [8] .
Microfracture involves debridement of unstable cartilage to bone level to form a stable rim of healthy cartilage around the defect. Specially designed awls are then used to make multiple holes 2-4 mm deep and 3-4 mm apart in the subchondral show repair tissue to be immature after six weeks, suggesting a longer rehabilitation period might be necessary [35] .
The procedure may be less-well suited to the patello-femoral joint or the tibia, which in one study showed deterioration after 18 months following microfracture [24] , or to lesions larger than 4 cm 2 , which have been reported to fair better after treatment with autologous chondrocyte transplantation [22, 23] . Complications include degenerative changes in the subchondral area, such as cysts, osseous overgrowth and intra-lesional osteophytes in approximately 33% of cases [24, 27] . The significance of these findings has not been proven, but changes to the subchondral plate likely underlie failed MF treatment [33] .
Microfracture is not a curative treatment, but it can provide relief for a number of years. However, doubts remain over the durability of the repair tissue produced, which is fibrocartilagenous and has inferior biomechanical properties compared to operation, but the longevity of the initial improvement was not consistent between studies [36] . Furthermore, a recent report of microfracture used to treat professional athletes concluded that 'from a strict scientific stand point an untreated control group would be valuable to demonstrate that microfracture does not just mirror the natural course of healing' [37] . There are currently no published studies comparing MF (or any other intervention) to an untreated control group. This should be an important future research goal.
Autologous osteochondral grafting / mosaicplasty
Autologous osteochondral allografting, also known as mosaicplasty, most commonly involves transplantation of small (less than 1cm 2 ) cylindrical cartilage plugs (Figure 2) . The use of different size plugs allows defect filling of more than 90%, and the graft needs to be perpendicular and flush to the surface to prevent catching with knee motion [17] .
This technique has the advantage of directly implanting hyaline cartilage onto the defect. The procedure may be done open or arthroscopically, and is not recommended in individuals over 50 years old [17] . Good to excellent results have been reported in 85-95% of treated defects of the femoral condyles, tibial surfaces and patellar/trochlear lesions [38] [39] [40] [41] [42] [43] .
It is important to note that repair using autologous tissue technique is most suited to small (less than 4 cm 2 ) lesions, being limited by the availability of donor tissue and by potential donor-site morbidity [17, 44] . Larger defects may be filled with allogenous cartilage tissue from a cadaveric donor, although this risks immunologic rejection and disease transmission from donor to recipient. Therefore osteochondral allografts are generally reserved for uncontained (not well-defined) lesions greater than 4 cm 2 where there is significant osseous damage [8] .
Autologous chondrocyte implantation
By 2003 more than 15,000 patients have undergone ACI worldwide [45] and it is now widely considered the frontline treatment for defects larger than 2 cm 2 [8] ( Figure   4 ). The procedure is recommended for ICRS grade III/IV lesions of the femoral condyle or trochlear region, but more recently has been used with success for patellar lesions. The optimum candidate is a highly motivated patient, less than 50-55 years old, with a high functional demand and high potential for compliance with the long-term rehabilitation required (reviewed in [8] ).
Indications
The size of a lesion best suited to ACI is still debated. Conventional thinking is that lesions less than 2-2.5 cm 2 may be treated initially with microfracture, and that ACI may be used in patients that continue to have pain after microfracture. However, 
Rehabilitation
Rehabilitation protocols vary widely, but always involve a long and cautious process, requiring high motivation and patient compliance. When planning rehabilitation it is important to remember that a biological healing process is occurring, which involves cell proliferation (0-6 weeks), matrix production (first 6 months), and matrix remodeling (6 months onward). Most protocols require reduced weight bearing for 10 weeks, aiming to avoid impact loading and twisting or shearing forces which might damage the repair tissue. One protocol uses a plaster of Paris for week one, then toe-touch weight bearing with flexion-extension exercises at weeks two-six [47] . From six weeks partial weight bearing is used, and from ten weeks full weight bearing is allowed. Other regimes use passive movement from day one onwards, which aims to stimulate implanted cells via mechanical signals as early as possible [48] . It ought to be noted that the ideal mobilization protocol aims to optimize the repair process, and it is tailored to the individual case. Well-contained lesions are protected by surrounding cartilage and may begin weight bearing at 4 weeks, whereas large poorly contained lesions should not bear weight fully until 8-12 weeks post-surgery [8] . mapping allows evaluation of collagen content (for review see [52] ).
Clinical results of ACI
Clinical results for ACI have been encouraging. Numerous case-series report positive effectiveness of ACI for treatment of knee AC defects, with follow-up now available more than 10 years post-procedure [53] [54] [55] [56] . Furthermore, there are randomised trials (RCT) comparing ACI to microfracture [20, 23, 57] and to mosaicplasty [58] , and these RCTs have been reviewed in an attempt to determine an optimum treatment for focal AC defects.
A Cochrane Collaboration meta-analysis identified four randomised control trials comparing ACI with microfracture or mosaicplasty that met their eligibility criteria [23, [58] [59] [60] [61] . One of these trials reported superior outcome for ACI versus mosaicplasty [58] , whilst the other trials did not find a superior treatment. In one study one year after treatment ACI was associated with a tissue regenerate that was superior to that of microfracture [23] . Overall, they could not find evidence to support ACI over microfracture or mosaicplasty, and concluded that further randomised trials are required. [64] . The authors' recommendation is that a large prospective trial be conducted and that non-operated controls be included.
These trials are consistent in reporting clinical improvement following ACI.
Furthermore, economic analysis has demonstrated cost effectiveness of ACI [65] .
There is emerging evidence that that the repair tissue produced in ACI is more hyaline-like and more durable than that following microfracture. [20, 62] . However, there is currently no firm evidence that ACI provides improved patient outcomes compared to either microfracture or mosaicplasty. Furthermore, the quality of trial methodology investigating knee AC defects could be improved by adequately describing randomisation procedures, including untreated control groups, use of validated outcome measures and the use of an independent investigator or outcome assessment [61, 66] .
Matrix-assisted/induced autologous chondrocyte implantation
Autologous chondrocyte implantation is considered to be the first widely available and commercially successful cell-based therapeutic intervention. Undoubtedly, in the future more cellular therapies will become available to treat a wide variety of disorders. The pioneering position of ACI at the forefront of medical technology has understandably led to close scrutiny from medical regulatory authorities. Wood et al. 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60 F o r P e e r R e v i e w O n l y included graft failure (25%), delamination (22%) and tissue hypertrophy (18%) [67] and most often occurs within 6 months after surgery in approximately 25% cases and can require surgery [54] .
It is thought that tissue hypertrophy is related to the use of a periosteal graft to cover the implanted chondrocytes, which in addition is technically difficult to harvest and can cause joint stiffness and arthrofibrosis. The technical advantages of scaffoldbased techniques (e.g. MACI), which remove the need for an arthrotomy and the risk of perosteal hypertrophy, have led to some surgeons preferring scaffold techniques [54] . Therefore, there has been evolution towards implants in which cells are seeded and CaReS (Ars Arthro, Esslingen, Germany). Mid-long term follow-up is now becoming available [68] , and suggests that MACI gives similar or slightly improved clinical outcome compared to ACI [47] or microfracture [56] . Biopsy results have also been encouraging, showing the production of hyaline cartilage [47, 50] .
Nevertheless, randomised trials are required to investigate these new procedures [69] .
Histological analysis of repair tissue following ACI/MACI reveals that approximately 50% of patients have hyaline-like or mixed hyaline and fibrocartilage tissue [20, 50] .
Although this is certainly improved compared to microfracture [62] , why some chondrocyte implants produce hyaline tissue and others fibro cartilaginous tissue is not known. This may be due to specific patient, cell-culture or knee injury factors, and investigation into predicting which patients respond best will be important in [16, 67] . The evidence for ACI providing superior outcomes compared with treatment by microfracture bone-marrow stimulation is not yet well established [61, 66] and improvement in the quality of randomised control trials that are undertaken is required [61, 66] . 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60 
